Daily Management of Patients on Multikinase Inhibitors' Treatment.

Colombo, Carla; De Leo, Simone; Trevisan, Matteo; Giancola, Noemi; Scaltrito, Anna; Fugazzola, Laura

Colombo, Carla; De Leo, Simone; Trevisan, Matteo; Giancola, Noemi; Scaltrito, Anna; Fugazzola, Laura.

Afiliação

Colombo C; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, Italiano, Milan, Italy.
De Leo S; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
Trevisan M; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, Italiano, Milan, Italy.
Giancola N; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, Italiano, Milan, Italy.
Scaltrito A; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, Italiano, Milan, Italy.
Fugazzola L; Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico, Italiano, Milan, Italy.

Front Oncol ; 12: 903532, 2022.

Article em En | MEDLINE | ID: mdl-35860593

Palavras-chave

Cabozantinib; Lenvatinib; MKI; QoL; Vandetanib; multidisciplinary tumor board; prehabilitation; thyroid cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google